Identification of plasma-derived exosomal miRNAs as potential targets for anti-PD-1 therapy in patients with lung cancer
| Top 10 miRNAs | logFC | logCPM | P value | FDR |
| hsa-miR-125b-5p | −2.12201 | 8.80358 | 7.69E−05 | 0.053356 |
| hsa-miR-1246 | −2.21223 | 6.7894305 | 0.001474 | 0.511533 |
| hsa-miR-1290 | −2.40124 | 5.7791914 | 0.002272 | 0.525701 |
| hsa-miR-144-5p | −1.5785 | 8.8879329 | 0.003899 | 0.676561 |
| hsa-miR-4676-3p | −5.39321 | 1.6555446 | 0.006068 | 0.719744 |
| hsa-miR-4433b-3p | 1.962046 | 9.7763291 | 0.006392 | 0.719744 |
| hsa-miR-744-5p | 0.985601 | 12.645567 | 0.007612 | 0.719744 |
| hsa-miR-7976 | −2.93799 | 3.7599466 | 0.009889 | 0.719744 |
| hsa-miR-877-5p | 1.539099 | 7.1799127 | 0.009925 | 0.719744 |
| hsa-miR-10b-3p | −3.14894 | 4.1456507 | 0.010937 | 0.719744 |
Differentially expressed miRNAs between PR-pre and PR-post samples were analyzed by exact test (logCPM>4, p<0.05, FDR≤0.1).
CPM, counts per million; FC, Fold change; FDR, false discovery rate.